BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16988550)

  • 1. A metabolic syndrome independent association between overweight, fibrinolysis impairment and low-grade inflammation in young women with venous thromboembolism.
    Salobir B; Sabovic M
    Blood Coagul Fibrinolysis; 2006 Oct; 17(7):551-6. PubMed ID: 16988550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group.
    Schulman S; Wiman B
    Thromb Haemost; 1996 Apr; 75(4):607-11. PubMed ID: 8743187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors.
    De Pergola G; Pannacciulli N; Coviello M; Scarangella A; Di Roma P; Caringella M; Venneri MT; Quaranta M; Giorgino R
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):227-32. PubMed ID: 17400434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent and opposite associations of hip and waist circumference with metabolic syndrome components and with inflammatory and atherothrombotic risk factors in overweight and obese women.
    Rocha PM; Barata JT; Teixeira PJ; Ross R; Sardinha LB
    Metabolism; 2008 Oct; 57(10):1315-22. PubMed ID: 18803932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
    Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.
    Crowther MA; Roberts J; Roberts R; Johnston M; Stevens P; Skingley P; Patrassi GM; Sartori MT; Hirsh J; Prandoni P; Weitz JI; Gent M; Ginsberg JS
    Thromb Haemost; 2001 Mar; 85(3):390-4. PubMed ID: 11307802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
    Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
    Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
    Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
    Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.
    Morimitsu LK; Fusaro AS; Sanchez VH; Hagemann CC; Bertini AM; Dib SA
    Diabetes Res Clin Pract; 2007 Dec; 78(3):340-8. PubMed ID: 17544539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
    Henkel E; Gallo S; Siegert G; Koehler C; Hanefeld M
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):327-34. PubMed ID: 17473573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between insulin resistance and some coagulation and fibrinolytic parameters in patients with metabolic syndrome.
    Ragab A; Abousamra NK; Higazy A; Saleh O
    Lab Hematol; 2008; 14(1):1-6. PubMed ID: 18403313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
    Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the pro-thrombotic state in CAPD patients.
    Preloznik Zupan I; Sabovic M; Salobir B; Buturovic Ponikvar J
    Ren Fail; 2008; 30(6):597-602. PubMed ID: 18661409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of moderate weight loss on anginal symptoms and indices of coagulation and fibrinolysis in overweight patients with angina pectoris.
    Hankey CR; Lean ME; Lowe GD; Rumley A; Woodward M
    Eur J Clin Nutr; 2002 Oct; 56(10):1039-45. PubMed ID: 12373626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of blood passage through the pulmonary circulation on fibrinolytic parameters.
    Kloboves-Prevodnik V; Sabovic M; Keber D
    Heart Vessels; 2004 Jan; 19(1):33-7. PubMed ID: 14685753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
    Salobir B; Sabovic M; Zupan IP; Ponikvar JB
    Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A; Wiman B; Schulman S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.